Ginkgo Bioworks Holdings, Inc. (DNA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Ginkgo Bioworks Holdings, Inc. (DNA)
Company Performance

Current Price

as of Oct 18, 2024

$8.88

P/E Ratio

N/A

Market Cap

$382.75M

Description

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Metrics

Overview

  • HQBoston, MA
  • SectorHealth Services
  • IndustryMedical/Nursing Services
  • TickerDNA
  • Price$8.88+5.97%

Trading Information

  • Market Cap$382.75M
  • Float67.40%
  • Average Daily Volume (1m)945,364
  • Average Daily Volume (3m)15,604,920
  • EPS-$18.03

Company

  • Revenue$184.33M
  • Rev Growth (1yr)-30.24%
  • Net Income-$217.18M
  • Gross Margin44.76%
  • EBITDA Margin-236.99%
  • EBITDA-$133.20M
  • EV$406.54M
  • EV/Revenue2.21
  • P/EN/A
  • P/S2.47
  • P/B0.52
Documents
SEC Filings
8-K (2024-09-04)
8-K (2024-08-19)
8-K (2024-08-15)
8-K (2024-06-14)
8-K (2024-05-13)
8-K (2024-05-09)
8-K (2024-03-14)
8-K (2024-02-29)
8-K (2024-01-10)
8-K (2023-11-08)
8-K (2023-10-27)
8-K (2023-10-03)
8-K (2023-08-29)
8-K (2023-08-23)
8-K (2023-08-09)
8-K (2023-06-20)
8-K (2023-05-10)
8-K (2023-05-05)
8-K (2023-03-10)
8-K (2023-03-01)
8-K (2023-01-27)
8-K (2023-01-11)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-08)
10-Q (2023-08-09)
10-Q (2023-05-10)
10-K (2024-02-29)
10-K (2023-03-13)
Factset Street Account
StreetAccount Metrics Recap - Ginkgo Bioworks Holdings Q3 Earnings ($1.49, 0.00) (2023-11-08T22:23:01Z)
StreetAccount Earnings Call Q&A Summary: Ginkgo Bioworks Holdings Q3 ($1.49, 0.00) (2023-11-09T01:11:19Z)
StreetAccount Consensus Metrics Preview - Ginkgo Bioworks Holdings Q3 Earnings ($1.58, +0.06) (2023-11-07T17:52:47Z)
QL AG announces partnership with Ginkgo Bioworks to develop dairy proteins ($1.75, 0.00) (2023-10-12T11:05:52Z)
Persephone Biosciences and Ginkgo Bioworks complete reusable bacteroides anaerobic engineering toolkit ($1.68, 0.00) (2023-10-17T11:04:36Z)
Ginkgo Bioworks Holdings reports Q3 EPS ($0.16) vs FactSet ($0.09) [7 est, ($0.10)-(0.07)] ($1.49, 0.00) (2023-11-08T22:05:45Z)
Ginkgo Bioworks Holdings downgraded to neutral from buy at BTIG ($1.49, 0.00) (2023-11-09T11:45:14Z)
Ginkgo Bioworks Holdings downgraded to market perform from outperform at Raymond James ($1.28, 0.00) (2023-11-14T12:57:18Z)
Ginkgo Bioworks Holdings discloses subsidiary Zymergen filed voluntary petitions for relief under Chapter 11 - 8-K ($1.71, 0.00) (2023-10-03T10:58:26Z)
Ginkgo Bioworks Holdings discloses slides for today's Investor day presentation ($1.69, -0.02) (2023-10-03T14:02:58Z)
Ginkgo Bioworks and XWELL announce implementation of expanded CDC traveler-based genomic surveillance program ($1.64, 0.00) (2023-11-06T12:09:38Z)
Foremost Farms selects Ginkgo Bioworks to develop technology for upcycling dairy co-products ($1.49, 0.00) (2023-11-09T12:12:51Z)
Concentric by Ginkgo partners with Penn State University on zoonotic disease Biosurveillance research ($1.49, 0.00) (2023-10-24T11:07:49Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-10)
Earnings Report (2023-08-10)
Factset
Factset Business Description
Wikipedia
Ginkgo_Bioworks_Holdings,_Inc.